BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment. Antimicrob Agents Chemother 2019:AAC. [PMID: 31591118 DOI: 10.1128/AAC.01215-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Melikyan N, Huerga H, Atshemyan H, Kirakosyan O, Sargsyants N, Aydinyan T, Saribekyan N, Khachatryan N, Oganezova I, Falcao J, Balkan S, Hewison C. Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe. Open Forum Infect Dis 2021;8:ofaa653. [PMID: 33634203 DOI: 10.1093/ofid/ofaa653] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Tunesi S, Dû DL, Gualano G, Millet J, Skrahin A, Bothamley G, Casas X, Goletti D, Lange C, Musso M, Palmieri F, Pourcher V, Rioux C, Skrahina A, Veziris N, Viatushka D, Jachym-fréchet M, Guglielmetti L. Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study. Journal of Infection 2022. [DOI: 10.1016/j.jinf.2022.03.004] [Reference Citation Analysis]
3 Arora U, Garg P, Agarwal S, Nischal N, Shalimar, Wig N. Complexities in the treatment of coinfection with HIV, hepatitis B, hepatitis C, and tuberculosis. Lancet Infect Dis 2021;21:e399-406. [PMID: 34023004 DOI: 10.1016/S1473-3099(20)30765-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]